Clinical trials: Metastatic Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back.
- Conditions
- Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
- Trial name
- NCT02068157
- Testing
- Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body.
- Trial name
- NCT00239200
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Michigan Rogel Cancer Center
HNSCC
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with…
- Trial name
- PEMDA-HN (NCT05814666)
- Testing
- Danvatirsen, Pembrolizumab
- Where
- 32 sites in United States, South Korea and 1 more
- Volunteers
- 69 people
- Sponsor
- Flamingo Therapeutics NV
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Penile Cancer
Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma
- Trial name
- ORPHEUS (NCT04231981)
- Testing
- Retifanlimab
- Where
- 13 sites in Italy, Spain
- Volunteers
- 18 people
- Sponsor
- MedSIR
Head and Neck Squamous Cell Carcinoma HNSCC
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
The trial focuses on assessing the role of [68Ga]Ga-FAPI-46 in head and neck squamous cell carcinomas (HNSCC) staging before surgery.
- Trial name
- FAPIHN (NCT06794372)
- Testing
- [68Ga]Ga-FAPI-46 PET/CT
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- John O. Prior
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Head and Neck Cancer, Squamous Cell Carcinoma
EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer
Head \& neck (H\&N) cancer is the eighth most common cancer in the UK. Advanced H\&N cancer which has come back after treatment or has spread to other parts of the body is incurable and the average life expectancy of these…
- Trial name
- EACH (NCT03494322)
- Testing
- Avelumab, Cetuximab
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University College, London
Head and Neck Squamous Cell Carcinoma
SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of first-line with recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with Recurrent and/or Metastatic Head and Neck Squamous…
- Trial name
- NCT03744208
- Testing
- Anti-EGFR monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Shi Yuankai
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Head and Neck Neoplasms
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
NC-6004 is a polymeric micelle containing cisplatin as an active moiety. The nanoparticle provides sustained release of the active moiety and utilizes the enhanced permeability and retention (EPR) effect to target release of…
- Trial name
- NCT02817113
- Testing
- NC-6004, Cetuximab, 5-FU
- Where
- 3 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Orient Europharma Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed…
- Trial name
- NCT04633278
- Testing
- CMP-001, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent…
- Trial name
- CPI (NCT07633613)
- Testing
- Blood sampling, Tumor biopsies for biobank establishment (optional)
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Esophageal Squamous Cell Carcinoma
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts.
- Trial name
- NCT03603756
- Testing
- SHR-1210, Apatinib, Irinotecan Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Cancer
A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer
The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens for locally advanced, recurrent, or metastatic esophageal squamous cell…
- Trial name
- NCT00995358
- Testing
- peptide
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- University of Yamanashi
Esophageal Squamous Cell Carcinoma
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2…
- Trial name
- NCT03116152
- Testing
- IBI308, paclitaxel/ irinotecan
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab and evaluates how well it works in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT06868433
- Testing
- Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.